{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:42:51Z","timestamp":1771476171829,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,22]],"date-time":"2024-01-22T00:00:00Z","timestamp":1705881600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jaad.2023.12.027","type":"journal-article","created":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T06:38:19Z","timestamp":1703399899000},"page":"935-944","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data"],"prefix":"10.1016","volume":"90","author":[{"given":"Joseph F.","family":"Merola","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brennan","family":"Ertmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Whitney","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2023.12.027_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the American Heart Association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2023.12.027_bib2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1111\/jth.12698","article-title":"Thrombosis: a major contributor to the\u00a0global disease burden","volume":"12","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jaad.2023.12.027_bib3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archinte.167.9.935","article-title":"Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom","volume":"167","author":"Huerta","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jaad.2023.12.027_bib4","doi-asserted-by":"crossref","first-page":"I9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jaad.2023.12.027_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular risk factors associated with venous thromboembolism","volume":"4","author":"Gregson","year":"2019","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jaad.2023.12.027_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002236","article-title":"Waiting for JAK inhibitor safety data","volume":"8","author":"Kragstrup","year":"2022","journal-title":"RMD Open"},{"key":"10.1016\/j.jaad.2023.12.027_bib7","series-title":"FDA Drug Safety Communication: FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, And Death for Jak Inhibitors that Treat Certain Chronic Inflammatory Conditions","year":"2021"},{"key":"10.1016\/j.jaad.2023.12.027_bib8","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10067-022-06415-5","article-title":"Cardiovascular risks associated with Janus kinase inhibitors: peering outside the black box","volume":"42","author":"Misra","year":"2022","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib9","series-title":"Scientific Conclusions and Grounds for the Variation to the Terms of the Marketing Authorisation: Barcitinib (EMEA\/H\/C\/PSUSA\/00010578\/201902)","year":"2019"},{"key":"10.1016\/j.jaad.2023.12.027_bib10","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2023.12.027_bib11","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/2012.jama.11741","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis and association with disease duration and hospitalization","volume":"308","author":"Holmqvist","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jaad.2023.12.027_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1136\/annrheumdis-2012-201669","article-title":"The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study","volume":"72","author":"Choi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.12.027_bib13","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1136\/annrheumdis-2022-eular.1238","article-title":"POS0519 relationship between disease activity and major adverse events in patients with rheumatoid arthritis on tofacitinib or TNF inhibitors: a post hoc analysis of ORAL surveillance","volume":"81","author":"Karpouzas","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.12.027_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/annrheumdis-2020-218419","article-title":"Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden","volume":"80","author":"Molander","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.12.027_bib15","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jaad.2023.12.027_bib16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(09)61963-2","article-title":"Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study","volume":"375","author":"Grainge","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2023.12.027_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1001\/jamadermatol.2021.4918","article-title":"Association of psoriasis with incident venous thromboembolism and peripheral vascular disease: a systematic review and meta-analysis","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13075-021-02703-8","article-title":"The association between psoriatic arthritis and venous thromboembolism: a population-based cohort study","volume":"24","author":"Gazitt","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jaad.2023.12.027_bib19","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.semarthrit.2021.04.008","article-title":"The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis","volume":"51","author":"Damian","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.jaad.2023.12.027_bib20","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1136\/annrheumdis-2018-214388","article-title":"Risk of venous thromboembolism in ankylosing spondylitis: a general population-based study","volume":"78","author":"Avi\u00f1a-Zubieta","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2023.12.027_bib21","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","article-title":"Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study","volume":"39","author":"Ogdie","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jaad.2023.12.027_bib22","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/07853890.2021.1942974","article-title":"Venous thrombotic events in psoriasis patients: a systematic review with meta-analysis","volume":"53","author":"Hillary","year":"2021","journal-title":"Ann Med"},{"key":"10.1016\/j.jaad.2023.12.027_bib23","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2014.12.013","article-title":"Association of atopic dermatitis with being overweight and obese: a systematic review and metaanalysis","volume":"72","author":"Zhang","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib24","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jaad.2016.07.017","article-title":"Association of atopic dermatitis with smoking: a systematic review and meta-analysis","volume":"75","author":"Kantor","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jaad.2017.09.074","article-title":"A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis","volume":"78","author":"Yu","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s13555-021-00538-4","article-title":"Risk of venous thromboembolism among patients with atopic dermatitis: a cohort study in a US administrative claims database","volume":"11","author":"Meyers","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jaad.2023.12.027_bib27","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1001\/jamadermatol.2022.3516","article-title":"Association of risk of incident venous thromboembolism with atopic dermatitis and treatment with janus kinase inhibitors: a systematic review and meta-analysis","volume":"158","author":"Chen","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib28","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1001\/jamadermatol.2021.1570","article-title":"Incidence of venous thromboembolism in patients with dermatologist-diagnosed chronic inflammatory skin diseases","volume":"157","author":"Schneeweiss","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib29","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.clinthera.2021.06.008","article-title":"Risk of thromboembolic events and associated risk factors, including treatments, in patients with immune-mediated diseases","volume":"43","author":"Setyawan","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaad.2023.12.027_bib30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00403-020-02099-6","article-title":"Association of inflammatory skin diseases with venous thromboembolism in US adults","volume":"313","author":"Shaheen","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.jaad.2023.12.027_bib31","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/01621459.1989.10478874","article-title":"The robust inference for the cox proportional hazards model","volume":"84","author":"Lin","year":"1989","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jaad.2023.12.027_bib32","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2147\/OARRR.S284757","article-title":"Venous thromboembolism in rheumatoid arthritis: the added effect of disease activity to traditional risk factors","volume":"14","author":"Omair","year":"2022","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.jaad.2023.12.027_bib33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.51821\/84.1.910","article-title":"Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms","volume":"84","author":"Coremans","year":"2021","journal-title":"Acta Gastroenterol Belg"},{"key":"10.1016\/j.jaad.2023.12.027_bib34","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2023.12.027_bib35","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1161\/ATVBAHA.118.311660","article-title":"TNF-\u0391 (tumor necrosis factor-\u03b1)","volume":"38","author":"Saha","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jaad.2023.12.027_bib36","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222303400X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S019096222303400X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,17]],"date-time":"2024-10-17T04:29:27Z","timestamp":1729139367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S019096222303400X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S019096222303400X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2023.12.027","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2023.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}